Eupraxia Pharmaceuticals Q2 EPS In Line
Eupraxia Pharmaceuticals reports Q2 EPS of $(0.23), meeting estimates
Eupraxia Pharmaceuticals (NASDAQ: EPRX ) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate.
This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.